Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;5(2):137-141.
doi: 10.1016/j.jpha.2014.10.001. Epub 2014 Oct 23.

Monolithic LC method applied to fesoterodine fumarate low dose extended-release tablets: Dissolution and release kinetics

Affiliations

Monolithic LC method applied to fesoterodine fumarate low dose extended-release tablets: Dissolution and release kinetics

Maximiliano S Sangoi et al. J Pharm Anal. 2015 Apr.

Abstract

A dissolution test for fesoterodine low dose extended-release tablets using liquid chromatographic (LC) method equipped with a C18 monolithic column was developed and validated. LC system was operated isocratically at controlled temperature (40 °C) using a mobile phase of acetonitrile:methanol:0.03 M ammonium acetate (pH 3.8) (30:15:55, v/v/v), run at a flow rate of 1.5 mL/min and detected at 208 nm. The best dissolution conditions for this formulation were achieved using a USP apparatus 2 (paddle) at 100 rpm and 900 mL of phosphate buffer at pH 6.8 as the dissolution medium. Validation parameters such as the specificity, linearity, accuracy, precision, and robustness were evaluated according to international guidelines, giving results within the acceptable range. The kinetic parameters of drug release were also investigated using model-dependent methods and the dissolution profiles were best described by the Higuchi model. The validated dissolution test can be applied for quality control of this formulation.

Keywords: Dissolution test; Fesoterodine; Low dose extended-release tablets; Monolithic LC; Release kinetics.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Chemical structure of fesoterodine fumarate.
Fig. 2
Fig. 2
Chromatograms of fesoterodine reference solution with UV spectra (A) and placebo sample solution (B) in dissolution medium. Chromatographic conditions: Phenomenex Onyx C18 monolithic column (100 mm×4.6 mm i.d.), 40 °C; mobile phase: acetonitrile:methanol:0.03 M ammonium acetate (pH 3.8) (30:15:55, v/v/v); flow rate: 1.5 mL/min; detection: 208 nm.
Fig. 3
Fig. 3
Dissolution profile of fesoterodine low dose extended-release tablets (n=6) in phosphate buffer pH 6.8 medium (37±0.5 °C) using apparatus 2 rotating at 100 rpm.
Fig. 4
Fig. 4
Graphical plots obtained by fitting experimental release data of fesoterodine to (A) zero-order, (B) first-order, (C) Higuchi, (D) Hixson–Crowell, and (E) Korsmeyer–Peppas models. R2, coefficient of determination; k, dissolution constants of respective mathematical models.
None

Similar articles

Cited by

References

    1. Costa P., Lobo J.M.S. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 2001;13:123–133. - PubMed
    1. Dash S., Murthy P.N., Nath L. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol. Pharm. Drug Res. 2010;67:217–223. - PubMed
    1. Gao Z. Mathematical modeling of variables involved in dissolution testing. J. Pharm. Sci. 2011;100:4934–4942. - PubMed
    1. Malhotra B., Guan Z., Wood N. Pharmacokinetic profile of fesoterodine. Int. J. Clin. Pharmacol. Ther. 2008;46:556–563. - PubMed
    1. Chapple C.R., Khullar V., Gabriel Z. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur. Urol. 2008;54:543–562. - PubMed

LinkOut - more resources